A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis

Barry J. Plant, Damian G Downey, Joe A Eustace, Cedric Gunaratnam, Charles S. Haworth, Andrew M. Jones, Edward F McKone, Daniel G Peckham, R Ian Ketchell, Diana Bilton

Research output: Contribution to journalArticle

305 Downloads (Pure)

Abstract

BACKGROUND: Studies are required that evaluate real-world outcomes of inhaled aztreonam lysine in patients with cystic fibrosis (CF).

METHODS: Our treatment-evaluator tool assessed the effectiveness of inhaled aztreonam in routine practice in 117 CF patients across four time periods (6-12 (P2) and 0-6months (P1) pre-initiation, and 0-6 (T1) and 6-12months (T2) post-initiation). Outcomes were: changes in %-predicted forced expiratory volume in 1s (FEV1), body-mass index (BMI), hospitalisation days and intravenous antibiotic usage.

RESULTS: Median FEV1% predicted for each 6-month period was 38.9%, 34.6%, 37.1% and 36.5%; median change was -2.0% between P2 and P1, increasing to +0.6% (p<0.001) between P1 and T1. Annualised hospital bed-days was reduced (p=0.05) post-initiation, as was intravenous antibiotics days (p=0.001). BMI increased over 6months post-initiation (p≤0.001).

CONCLUSIONS: In patients with CF in routine practice, inhaled aztreonam lysine is associated with improved lung function and weight, and reduced hospitalisation and intravenous antibiotic use.

Original languageEnglish
Number of pages7
JournalJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Early online date06 Apr 2017
DOIs
Publication statusEarly online date - 06 Apr 2017

Keywords

  • Journal Article

Fingerprint Dive into the research topics of 'A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis'. Together they form a unique fingerprint.

  • Cite this